Cargando…

Prognostic analysis of three forms of Ki‐67 in patients with breast cancer with non‐pathological complete response before and after neoadjuvant systemic treatment

BACKGROUND: Patients who do not achieve a pathological complete response (pCR) after neoadjuvant systemic treatment (NST) have a significantly worse prognosis. A reliable predictor of prognosis is required to further subdivide non‐pCR patients. To date, the prognostic role in terms of disease‐free s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Weiwei, Xu, Yinggang, Wang, Ye, He, Jinzhi, Chen, Rui, Wan, Xinyu, Shi, Wenjie, Huang, Xiaofeng, Shi, Xiaoqing, Wang, Jue, Zha, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166904/ https://www.ncbi.nlm.nih.gov/pubmed/36794698 http://dx.doi.org/10.1002/cam4.5693

Ejemplares similares

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response
por: Xu, Yinggang, et al.
Publicado: (2023)

A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer
por: Shi, Wenjie, et al.
Publicado: (2022)

Corrigendum: A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer
por: Shi, Wenjie, et al.
Publicado: (2022)

Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis
por: Xu, Yinggang, et al.
Publicado: (2022)

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
por: Burcombe, Russell, et al.
Publicado: (2006)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

Ki-67 and Its Relation With Complete Pathological Response in Patients With Breast Cancer
por: Wajid, Sana, et al.
Publicado: (2021)

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)

Prognostic and clinicopathological value of Ki-67 expression in patients with nasopharyngeal carcinoma: a meta-analysis
por: Shi, Zhaohui, et al.
Publicado: (2020)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Kim, Taeryung, et al.
Publicado: (2015)

Correlation between preoperative inflammatory markers, Ki-67 and the pathological grade of glioma
por: Xu, Guangda, et al.
Publicado: (2021)

The relationship between Ki-67 expression and imaging signs and pathological features in GISTs
por: Xiao, Lin, et al.
Publicado: (2023)

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
por: Chen, Rui, et al.
Publicado: (2018)

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
por: Bouzubar, N., et al.
Publicado: (1989)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors
por: Wang, Hai-Yue, et al.
Publicado: (2019)

General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67
por: Sipos, Tamás-Csaba, et al.
Publicado: (2023)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
por: Ingolf, Juhasz-Böss, et al.
Publicado: (2014)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer
por: Imaizumi, Ken, et al.
Publicado: (2019)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Correlation between apparent diffusion coefficient and Ki-67 in different pathological types of lung cancer
por: Ren, Hongna, et al.
Publicado: (2021)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer
por: Sinn, Hans-Peter, et al.
Publicado: (2017)

Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
por: Paek, Kyung-Il, et al.
Publicado: (2005)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients
por: Wu, Yu-tuan, et al.
Publicado: (2018)

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
por: Calhoun, Benjamin C., et al.
Publicado: (2016)

Use of Ultrasound and Ki–67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy
por: Liebscher, Sean C., et al.
Publicado: (2023)

The relationship between the expression of Ki-67 and the prognosis of osteosarcoma
por: Zeng, Ming, et al.
Publicado: (2021)

Quantifying the Ki-67 Heterogeneity Profile in Prostate Cancer
por: Mesko, Shane, et al.
Publicado: (2013)

Immunolocalization of Ki-67 in different periodontal conditions
por: Preethi, Penubolu Lakshmi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qudstr0vqkpt0mrg6t29jssihm